Equities analysts forecast that Quanterix Corp (NASDAQ:QTRX) will post ($0.28) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Quanterix’s earnings, with estimates ranging from ($0.29) to ($0.26). The business is scheduled to issue its next quarterly earnings report on Friday, November 9th.
On average, analysts expect that Quanterix will report full year earnings of ($1.20) per share for the current fiscal year, with EPS estimates ranging from ($1.24) to ($1.16). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.77) per share, with EPS estimates ranging from ($0.95) to ($0.58). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Quanterix.
Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Friday, August 10th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The business had revenue of $8.64 million for the quarter, compared to analyst estimates of $7.92 million.
A number of equities research analysts have weighed in on QTRX shares. Zacks Investment Research cut shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th. BTIG Research reissued a “buy” rating and issued a $26.00 price objective on shares of Quanterix in a research note on Sunday, May 13th. Finally, ValuEngine raised shares of Quanterix from a “hold” rating to a “buy” rating in a research note on Monday, June 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $26.50.
Several hedge funds and other institutional investors have recently bought and sold shares of QTRX. Schwab Charles Investment Management Inc. purchased a new position in shares of Quanterix in the first quarter valued at approximately $374,000. Northern Trust Corp purchased a new position in shares of Quanterix in the first quarter valued at approximately $894,000. BlackRock Inc. purchased a new position in shares of Quanterix in the first quarter valued at approximately $3,439,000. Citadel Advisors LLC purchased a new position in shares of Quanterix in the first quarter valued at approximately $431,000. Finally, Opaleye Management Inc. boosted its stake in shares of Quanterix by 130.8% in the first quarter. Opaleye Management Inc. now owns 150,000 shares of the company’s stock valued at $2,556,000 after purchasing an additional 85,000 shares during the period. 49.14% of the stock is owned by institutional investors and hedge funds.
Shares of QTRX traded down $0.25 during trading on Thursday, reaching $14.57. 48,700 shares of the company traded hands, compared to its average volume of 98,842. Quanterix has a twelve month low of $13.00 and a twelve month high of $24.81. The stock has a market cap of $369.73 million and a PE ratio of -1.78.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Featured Article: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.